Welcome to our dedicated page for ADC Therapeutics SA SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA director Viviane Monges reported routine equity compensation and related tax withholding. She was granted 45,000 restricted stock units for her service as a director under the company’s 2019 Equity Incentive Plan, with each unit representing one common share.
In a separate transaction tied to the vesting of previously granted restricted share units, 2,596 common shares were withheld by the company to satisfy her tax withholding obligations at a price of $3.08 per share. After these transactions, she directly owns 186,447 common shares. These events reflect compensation and tax mechanics, not open-market share purchases or sales.
ADC Therapeutics SA director Peter Hug reported routine equity compensation activity. On June 1, 2026, he received a grant of 45,000 Common Shares in the form of restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for service as a director.
The RSUs vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, subject to his continued service. On June 3, 2026, 2,156 Common Shares were withheld by the company to satisfy his tax withholding obligations upon vesting of previously granted RSUs, a non-market, tax-related disposition rather than an open-market sale.
Following these transactions, Hug directly holds 263,344 Common Shares of ADC Therapeutics SA.
ADC Therapeutics SA director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for board service. The RSUs vest on the earlier of one year from the grant date or the 2027 annual shareholder meeting, and each RSU converts into one common share.
To cover tax withholding on previously vested RSUs, the company withheld 12,600 common shares at $3.08 per share. After these compensation-related transactions, Bizzari directly holds 139,302 common shares.
ADC Therapeutics SA director Timothy Coughlin reported routine equity compensation activity. On June 1, 2026, he received an annual grant of 45,000 common shares in the form of restricted stock units under the company’s 2019 Equity Incentive Plan for service as a director.
On June 3, 2026, 12,600 common shares were withheld by the company to cover his tax obligations when previously granted restricted share units vested. This tax withholding is shown as a disposition but is not an open‑market sale. After these transactions, he directly holds 72,400 common shares.
ADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B‑cell lymphoma. The study met its primary endpoint: progression‑free survival improved to a median 6.1 months versus 4.7 months with R‑GemOx (hazard ratio 0.73; p=0.008).
Overall response rate was higher at 58.1% versus 45.2%, with complete responses of 39.5% versus 26.7%. Median duration of response was 9.2 versus 7.7 months and complete responses lasted 16.8 versus 12.3 months, with 48.5% versus 16.7% of complete responders still in remission at 24 months.
Overall survival showed no detrimental effect (hazard ratio 0.96). Safety was mixed: overall treatment‑emergent adverse event rates were similar, but serious events, withdrawals, and Grade 5 events were higher with ZYNLONTA plus rituximab (Grade 5 in 13.2% versus 4.6%, mostly in patients aged 75 or older). The company plans a pre‑sBLA FDA meeting in August and a supplemental BLA submission in the fourth quarter of 2026.
ADC Therapeutics reported that shareholders approved all proposals at the 2026 annual general meeting on June 1, 2026. Investors endorsed the 2025 financial statements, discharged the board and executive committee from liability, and reelected all directors, compensation committee members, the Independent Proxy and PricewaterhouseCoopers as auditor.
Shareholders approved, on a binding Swiss-law basis, maximum board compensation of $2,500,000, fixed executive committee pay of $2,600,000 for 2027, and variable executive compensation of up to $5,500,000 for 2026. They also approved an amendment increasing shares authorized under the 2019 Equity Incentive Plan.
Key capital changes included raising the Company’s capital range to between CHF 10,378,109.12 and CHF 15,567,163.68, increasing conditional share capital for employee participation to 16,836,253 common shares, and for financing and acquisitions to 48,026,929 common shares, alongside introducing a new conditional share capital article based on the capital range.
ADC Therapeutics reported Q1 2026 net revenue of $20.9 million, down 9.5% year over year as prior-year milestone revenue dropped, while U.S. ZYNLONTA product sales rose to $20.0 million, up 15.1% on higher volume and pricing.
The company posted a net loss of $33.0 million, improved from $38.6 million, as research and development expense fell 31.3% to $19.9 million following its 2025 restructuring, partly offset by higher selling and marketing costs of $12.7 million.
ADC Therapeutics ended the quarter with $231.0 million in cash and cash equivalents. Long-term obligations remain significant, including a $319.6 million deferred royalty obligation and $115.7 million of senior secured term loans, plus HCR warrants for 9.8 million shares issued in a February 2026 amendment to its royalty agreement.
ADC Therapeutics reported first quarter 2026 results, highlighting growing product sales but continuing losses. Net product revenue from ZYNLONTA reached $20.0 million, up from $17.4 million a year earlier, while total revenue was $20.9 million versus $23.0 million due to lower license revenue and royalties.
The company recorded a net loss of $33.0 million, improving from a $38.6 million loss in first quarter 2025. Adjusted net loss narrowed to $19.7 million, or $0.13 per share, from $24.0 million, or $0.22 per share, mainly driven by lower research and development spending.
Cash and cash equivalents were $231.0 million as of March 31, 2026, down from $261.3 million at year end 2025, and the company expects its cash runway to extend at least into 2028. Management also reiterated key clinical milestones, including LOTIS-5 Phase 3 topline data expected in the second quarter of 2026 and full LOTIS-5 and LOTIS-7 data anticipated by year end.
ADC Therapeutics beneficial ownership disclosure: Redmile Group, LLC and related entities report shared beneficial ownership of 12,717,487 shares of Common Shares, representing 9.9% of the class. The filing states 7,780,431 shares (6.1%) are held by RedCo II Offshore SPV LLC, and the percentages are calculated using 127,189,572 shares outstanding as of April 16, 2026 plus 112,602 shares issuable under certain Pre-Funded Warrants subject to a Beneficial Ownership Limitation. The filing also describes an internal reorganization shifting holdings from RedCo II Master Fund, L.P. to its SPVs; RedCo II Master reports 0 shares following the reorganization.
ADC Therapeutics is calling a virtual 2026 annual meeting on June 1, 2026 to vote on governance, compensation and capital matters. Shareholders of record on April 16, 2026, when 127,189,572 common shares were outstanding, may participate and vote online.
Key proposals include approving 2025 financial statements, the Swiss and U.S. compensation reports, discharging directors and executives from liability, carrying forward the 2025 loss, and reelecting directors, compensation committee members, the independent proxy and auditors. Shareholders will also vote on director and executive pay, an increase to the 2019 Equity Incentive Plan share authorization, and amendments to expand the company’s capital range and conditional share capital. The board recommends voting FOR all items.
The proxy also details 2025 pay practices. Corporate goals under the annual incentive plan were achieved at 125%, driven by $73.6 million in Zynlonta net sales, progress in clinical programs, restructuring to focus on Zynlonta, and financings that extended the expected cash runway into at least mid‑2028. This resulted in bonuses of $582,063 for CEO Ameet Mallik, $328,255 for CFO Jose Carmona and $431,325 for CMO Mohamed Zaki. Long‑term incentives were delivered mainly as time‑vested RSUs with double‑trigger change‑in‑control protection, and the company maintains a clawback policy and restrictions on hedging and pledging.